Pharmaceuticals, Biotechnology and Life Sciences
– Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…
IRVINE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVUS&src=ctag" target="_blank"gt;$NVUSlt;/agt;–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with…
IRVINE, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24NVUS&src=ctag" target="_blank"gt;$NVUSlt;/agt;–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with…
Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…
Conference Call Begins at 4:30 p.m. Eastern Time Today SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results…
– Product Sales of $5.2 billion –– Diluted EPS of $1.54 per share –– Non-GAAP Diluted EPS of $1.76 per…
Revenues of $4.3 billion GAAP diluted loss per share of $0.10 Non-GAAP diluted EPS of $0.60 Free cash flow of…
Cellgene and bluebird bio are are encouraged by the expansion and persistence ofthe CAR T-cells, as well as the deep and durable responses with amanageable safety profile we’ve seen for bb2121 to date
DUBLIN–(BUSINESS WIRE)–The “Arrhythmias – Pipeline Review, H1 2019” report has been added to ResearchAndMarkets.com’s offering. This latest pipeline guide Arrhythmias…